|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
U-M researchers discover new genes that fuse in cancer
New technology for detecting gene fusions opens field in cancer research--added 1/12/09
Ann Arbor, MI. -- Using new technologies that make it easier to sequence the human genome, researchers at the University of Michigan Comprehensive Cancer Center have identified a series of genes that become fused when their chromosomes trade places with each other. These recurrent gene fusions are thought to be the driving mechanism that causes certain cancers to develop.
The gene fusions discovered could potentially serve as a marker one day for diagnosing cancer or as a target for future drug development.
In the new study, published in Nature, the researchers identified several gene fusions in prostate cancer cells. Some of the fusions were seen in multiple cell lines studied, while other gene fusions appeared only once. The fusions were found only in cancer cells, and not in normal cells.
"We defined a new class of mutations in prostate cancer. The recurrent fusions are thought to be the driving mechanism of cancer. But we found other fusions as well, some of which were unique to individual patients. Our next step is to understand if these play a role in driving disease," says Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Endowed Professor of Pathology at the U-M Medical School.
Chinnaiyan's team was the first to identify rearrangements in chromosomes and fused genes in prostate cancer. Gene fusions had previously been known to play a role in blood cell cancers such as leukemia and lymphoma, and in Ewing's sarcoma.
In the current study, the researchers showed that newer techniques could identify these gene fusions more quickly and easily.
The researchers used a technique called gene sequencing, which involves creating a library of all RNAs in a cell. Sequencing machines then run 24 hours a day for days at a time, reading the RNA. Once the sequencing is finished, researchers study the data searching for the gene fusions.
This is a more direct approach than the method Chinnaiyan's lab used to first identify gene fusions in prostate cancer, a process called microarray. Using microarray technology, researchers had to first know where they wanted to look. With gene sequencing, the researchers can find what's there without knowing where to look first.
"We now have the ability to use next generation sequencing technology. This will open up the field in cancer research," says Chinnaiyan, a Howard Hughes Medical Institute investigator. While the current study focused on prostate cancer, his team is also looking at gene fusions involved in breast cancer, lung cancer and melanoma.
The FindingsResearchers tested gene sequencing technology to see if they could re-discover the same gene fusions previously found using other technologies. In addition to verifying the known gene fusions, researchers found new gene fusions that were common among some tumor samples. Additional gene fusions were identified in individual tumor samples.
Additional authorsChristopher Maher, Ph.D., research fellow; Chandan Kumar-Sinha, Ph.D., research assistant professor of pathology; Xuhong Cao, research specialist; Shanker Kalyana-Sundaram, data architect; Bo Han, research fellow; Xiaojun Jing, Lee Sam, Terrence Barrette, systems analyst; and Nallasivam Palanisamy, Ph.D., research assistant professor of pathology
FundingNational Institutes of Health, Department of Defense and Early Detection Research Network, American Association of Cancer Research Amgen Fellowship in Clinical/Translational Research, Canary Foundation and American Cancer Society Early Detection Postdoctoral Fellowship
Reference: Nature, published online Jan. 11, 2009, DOI: 10.1038/nature07638
ResourcesU-M Cancer AnswerLine™, 800-865-1125
Written by Nicole Fawcett